Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals announced that the European Medicines Agency's Committee for Orphan Medicinal Products has issued a positive opinion recommending orphan drug designation for Imsidolimab, its investigational monoclonal antibody, for the treatment of generalized pustular psoriasis. This marks the first time the EMA has formally recognized GPP as an orphan disease in Europe. The designation follows similar regulatory recognitions in the United States and Japan, and a Biologics License Application for Imsidolimab in GPP is currently under review by the FDA with a target action date of December 12, 2026. Vanda's CEO stated the positive opinion reinforces encouraging clinical data and highlights the urgent unmet medical need in GPP. The stock closed Thursday at $5.45, down 6.84%, but rose 4.19% to $5.68 in after-hours trading.

H.C. Wainwright reiterated a Buy rating on Vanda Pharmaceuticals with a price target of $21. The rating follows a Federal Register notice regarding Vanda's pursuit of FDA approval for HETLIOZ as a jet lag treatment. The FDA initially declined approval, but granted Vanda a formal evidentiary hearing—the first such hearing for any drug in over 40 years. A pre-hearing conference is set for July 20, 2026, with the actual hearing expected before year-end. The analyst noted that securing the jet lag indication could allow Vanda to generate branded prescription sales largely insulated from generic competition, despite existing generic tasimelteon on the market.

The global insomnia treatment market is projected to grow robustly through 2036, fueled by rising disease awareness and a pipeline of emerging therapies. In 2025, diagnosed prevalent cases of insomnia across the seven major markets—the United States, the EU4, the United Kingdom, and Japan—were estimated at approximately 90 million, with the United States accounting for the largest market share. Key pipeline candidates include Johnson & Johnson's Seltorexant, Vanda Pharmaceuticals' HETLIOZ, Idorsia's Daridorexant, and EUSOL Biotech's SM-1, which are expected to reshape the competitive landscape alongside recently approved orexin receptor antagonists such as VORZZZ in Japan. The market is also benefiting from the launch of novel drug classes like orexin antagonists and melatonin agonists, as well as increased adoption of cognitive behavioral therapy for insomnia.